COMPOSITION:

Each film-coated tablet contains Momelotinib dihydrochloride monohydrate 121.94 mg equivalent to Momelotinib………….100 mg.

INDICATION:  

LuciMomel is a kinase inhibitor indicated for the treatment of intermediate or high-risk myelofibrosis (MF), including primary MF or secondary MF [postpolycythemia vera (PV) and post-essential thrombocythemia (ET)], in adults with anemia.

DOSAGE AND USE:

• Recommended dosage: 200 mg orally once daily.

• Severe hepatic impairment (Child-Pugh Class C): Reduce the starting dose to 150 mg orally once daily.

Swallow tablets whole with or without food.

STORAGE:

In a dry place and store at 20°C to 25°C.

MANUFACTURED AND MARKETED BY: 

LUCIUS PHARMACEUTICALS(LAO) CO., LTD

No.26, Thongmang village, Xaythany district, Vientiane Capital, Laos

WARNING:

Keep medicine out of reach of Children. Do not administer LuciMomel during Pregnancy and Lactation.